New approaches to pharmacological treatment of osteoporosis.
(2003) In Bulletin of the World Health Organization 81(9). p.657-664- Abstract
- Osteoporosis has been recognized as a major public health problem for less than two decades. The increasing incidence
of fragility fractures, such as vertebral, hip, and wrist fractures, first became apparent from epidemiological studies in the early and
mid-1980s, when effective treatment was virtually unavailable. Pharmacological therapies that effectively reduce the number of
fractures by improving bone mass are now available widely in countries around the world. Most current agents inhibit bone loss
by reducing bone resorption, but emerging therapies may increase bone mass by directly promoting bone formation — as is the
case with parathyroid hormone. Current treatment alternatives include... (More) - Osteoporosis has been recognized as a major public health problem for less than two decades. The increasing incidence
of fragility fractures, such as vertebral, hip, and wrist fractures, first became apparent from epidemiological studies in the early and
mid-1980s, when effective treatment was virtually unavailable. Pharmacological therapies that effectively reduce the number of
fractures by improving bone mass are now available widely in countries around the world. Most current agents inhibit bone loss
by reducing bone resorption, but emerging therapies may increase bone mass by directly promoting bone formation — as is the
case with parathyroid hormone. Current treatment alternatives include bisphosphonates, calcitonin, and selective estrogen receptor
modulators, but sufficient calcium and vitamin D are a prerequisite. The availability of evidence-based data that show reductions
in the incidence of fractures of 30–50% during treatment has been a major step forward in the pharmacological prevention
of fractures. With all agents, fracture reduction is most pronounced for vertebral fracture in high-risk individuals; alendronate and
risedronate also may protect against hip fracture in the elderly. New approaches to pharmacological treatment will include further
development of existing drugs, especially with regard to tolerance and frequency of dosing. New avenues for targeting the condition
will emerge as our knowledge of the regulatory mechanisms of bone remodelling increases, although issues of tissue specificity
may be difficult to solve. In the long term, information gained through knowledge of bone genetics may be used to adapt
pharmacological treatments more precisely to each individual. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/120273
- author
- Åkesson, Kristina LU
- organization
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Fractures: etiology, Female, Diphosphonates: therapeutic use, Calcium, Risk Factors, Vitamin D: therapeutic use, Bone and Bones: metabolism, Calcitonin: therapeutic use, Dietary: therapeutic use, Postmenopausal: drug therapy, Osteoporosis, Postmenopausal: complications, Human
- in
- Bulletin of the World Health Organization
- volume
- 81
- issue
- 9
- pages
- 657 - 664
- publisher
- World Health Organization
- external identifiers
-
- pmid:14710507
- wos:000185876300007
- scopus:0141989663
- ISSN
- 0042-9686
- language
- English
- LU publication?
- yes
- id
- f9b19b53-59bb-49f0-a3ff-225fdc8cb26c (old id 120273)
- alternative location
- http://www.who.int/bulletin/volumes/81/9/Akesson0903.pdf
- date added to LUP
- 2016-04-01 12:01:59
- date last changed
- 2022-01-26 21:50:42
@article{f9b19b53-59bb-49f0-a3ff-225fdc8cb26c,
abstract = {{Osteoporosis has been recognized as a major public health problem for less than two decades. The increasing incidence<br/><br>
of fragility fractures, such as vertebral, hip, and wrist fractures, first became apparent from epidemiological studies in the early and<br/><br>
mid-1980s, when effective treatment was virtually unavailable. Pharmacological therapies that effectively reduce the number of<br/><br>
fractures by improving bone mass are now available widely in countries around the world. Most current agents inhibit bone loss<br/><br>
by reducing bone resorption, but emerging therapies may increase bone mass by directly promoting bone formation — as is the<br/><br>
case with parathyroid hormone. Current treatment alternatives include bisphosphonates, calcitonin, and selective estrogen receptor<br/><br>
modulators, but sufficient calcium and vitamin D are a prerequisite. The availability of evidence-based data that show reductions<br/><br>
in the incidence of fractures of 30–50% during treatment has been a major step forward in the pharmacological prevention<br/><br>
of fractures. With all agents, fracture reduction is most pronounced for vertebral fracture in high-risk individuals; alendronate and<br/><br>
risedronate also may protect against hip fracture in the elderly. New approaches to pharmacological treatment will include further<br/><br>
development of existing drugs, especially with regard to tolerance and frequency of dosing. New avenues for targeting the condition<br/><br>
will emerge as our knowledge of the regulatory mechanisms of bone remodelling increases, although issues of tissue specificity<br/><br>
may be difficult to solve. In the long term, information gained through knowledge of bone genetics may be used to adapt<br/><br>
pharmacological treatments more precisely to each individual.}},
author = {{Åkesson, Kristina}},
issn = {{0042-9686}},
keywords = {{Fractures: etiology; Female; Diphosphonates: therapeutic use; Calcium; Risk Factors; Vitamin D: therapeutic use; Bone and Bones: metabolism; Calcitonin: therapeutic use; Dietary: therapeutic use; Postmenopausal: drug therapy; Osteoporosis; Postmenopausal: complications; Human}},
language = {{eng}},
number = {{9}},
pages = {{657--664}},
publisher = {{World Health Organization}},
series = {{Bulletin of the World Health Organization}},
title = {{New approaches to pharmacological treatment of osteoporosis.}},
url = {{https://lup.lub.lu.se/search/files/2751753/623941.pdf}},
volume = {{81}},
year = {{2003}},
}